Next-gen gene editing upstart is grabbing the brass ring with a $150M crossover play to back its bid on a cure for sickle cell disease
Back in the spring of 2014, Versant put together a tidy $25 million launch round for a small upstart with big dreams called CRISPR Therapeutics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
